Independent Advisor Alliance grew its position in Eli Lilly And Co (NYSE:LLY) by 10.1% during the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 26,459 shares of the company’s stock after acquiring an additional 2,437 shares during the quarter. Independent Advisor Alliance’s holdings in Eli Lilly And Co were worth $2,838,000 at the end of the most recent reporting period.
Other institutional investors and hedge funds have also recently made changes to their positions in the company. Integrated Wealth Concepts LLC bought a new position in shares of Eli Lilly And Co in the second quarter worth about $103,000. Bay Colony Advisory Group Inc d b a Bay Colony Advisors bought a new position in shares of Eli Lilly And Co in the second quarter worth about $114,000. Fort L.P. bought a new position in shares of Eli Lilly And Co in the second quarter worth about $121,000. Welch Group LLC bought a new position in Eli Lilly And Co during the 3rd quarter worth about $123,000. Finally, Financial Management Professionals Inc. bought a new position in Eli Lilly And Co during the 2nd quarter worth about $128,000. 76.91% of the stock is currently owned by institutional investors and hedge funds.
In other news, major shareholder Lilly Endowment Inc sold 190,000 shares of the firm’s stock in a transaction dated Thursday, August 30th. The shares were sold at an average price of $105.42, for a total value of $20,029,800.00. Following the sale, the insider now directly owns 119,970,804 shares in the company, valued at approximately $12,647,322,157.68. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, major shareholder Eli & Co Lilly sold 700,000 shares of the firm’s stock in a transaction dated Tuesday, November 6th. The shares were sold at an average price of $14.00, for a total transaction of $9,800,000.00. Following the completion of the sale, the insider now owns 3,148,647 shares in the company, valued at $44,081,058. The disclosure for this sale can be found here. Insiders sold a total of 2,127,900 shares of company stock worth $165,108,695 over the last 90 days. Company insiders own 0.11% of the company’s stock.
Shares of Eli Lilly And Co stock opened at $112.87 on Monday. The company has a current ratio of 1.91, a quick ratio of 1.53 and a debt-to-equity ratio of 0.83. Eli Lilly And Co has a 1 year low of $73.69 and a 1 year high of $116.61. The stock has a market cap of $119.57 billion, a price-to-earnings ratio of 26.37, a price-to-earnings-growth ratio of 1.76 and a beta of 0.29.
Eli Lilly And Co (NYSE:LLY) last released its quarterly earnings results on Tuesday, November 6th. The company reported $1.39 earnings per share for the quarter, beating analysts’ consensus estimates of $1.35 by $0.04. Eli Lilly And Co had a net margin of 1.85% and a return on equity of 42.84%. The business had revenue of $6.06 billion for the quarter, compared to analysts’ expectations of $6.04 billion. During the same period last year, the business earned $1.05 EPS. The company’s revenue was up 7.1% compared to the same quarter last year. As a group, equities research analysts forecast that Eli Lilly And Co will post 5.58 earnings per share for the current fiscal year.
The company also recently declared a quarterly dividend, which will be paid on Monday, December 10th. Stockholders of record on Thursday, November 15th will be issued a $0.5625 dividend. This represents a $2.25 dividend on an annualized basis and a dividend yield of 1.99%. The ex-dividend date is Wednesday, November 14th. Eli Lilly And Co’s dividend payout ratio is currently 52.57%.
TRADEMARK VIOLATION WARNING: This news story was originally posted by WKRB News and is owned by of WKRB News. If you are reading this news story on another domain, it was illegally copied and republished in violation of U.S. & international trademark and copyright law. The legal version of this news story can be accessed at https://www.wkrb13.com/2018/11/26/eli-lilly-and-co-lly-stake-raised-by-independent-advisor-alliance.html.
Eli Lilly And Co Profile
Eli Lilly and Company discovers, develops, manufactures, and markets pharmaceutical products worldwide. The company operates through two segments, Human Pharmaceutical Products and Animal Health Products. It offers endocrinology products for the treatment of diabetes; osteoporosis in postmenopausal women and men; and human growth hormone deficiency and pediatric growth conditions.
Featured Story: How to Calculate Compound Annual Growth Rate (CAGR)
Want to see what other hedge funds are holding LLY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Eli Lilly And Co (NYSE:LLY).
Receive News & Ratings for Eli Lilly And Co Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly And Co and related companies with MarketBeat.com's FREE daily email newsletter.